Avai Bio, Inc.

AVAI BIO, INC. is a U.S.-based technology company that has evolved through several name changes, including Avant Technologies Inc. and Trend Innovations Holding Inc. The company describes its core focus as acquiring, creating, and developing AI-enabled technologies while also offering information technology consulting services. Its reported assets and initiatives include the Avant! AI text-generation system, a joint venture and license arrangement with Ainnova Tech, and software/data-service capabilities such as full-stack development, database management, data integration, project management, and cloud services. The company also previously owned a news-aggregation app through Thy News LLC and pursued technology asset acquisitions such as Wired4Health, although that transaction was later canceled. AVAI BIO is still in an early commercialization stage and has not yet generated meaningful revenue from its platforms.

0.03

— Avai Bio, Inc.
%
AI platforms and software assets45% Includes the Avant! AI system and other AI-related technologies the company acquires or develops.
IT consulting and implementation services25% Covers consulting, project management, and technology integration services for clients.
Cloud and data infrastructure services20% Includes cloud services, database management, and data integration capabilities.
Digital media and consumer app products10% Includes the Thy News news-aggregation application and related paid features.

The company’s customer base appears to be a mix of enterprise technology users, software and data-services clients, and...

  • Enterprise IT and consulting clientsprimary

    Buy software development, database, integration, and cloud services to support internal systems and projects.

  • AI platform users and license partnersprimary

    Adopt or license Avant! AI-related capabilities for text generation and AI workflow use cases.

  • Consumer news app userssecondary

    Use the Thy News application for customizable news feeds and potential paid premium features.

  • Strategic acquisition and JV counterpartiessecondary

    Provide technology assets, licenses, or development rights that the company uses to build its product base.

AVAI BIO is headquartered in the United States operationally, with a virtual office in Las Vegas, Nevada, while its...

  • •United States is the main operating base and reporting jurisdiction
  • •Las Vegas virtual office supports administrative operations
  • •Vilnius, Lithuania is the registered office location
  • •No country-level revenue disclosure was provided in the reports
  • •Current geography reflects corporate setup more than sales concentration
  • •Future exposure will depend on where AI and consulting products are commercialized

The company’s strategy is centered on building an AI-oriented technology portfolio through acquisitions, licensing, and...

01
Commercialize acquired AI technologiesshort-term

The company needs to turn acquired AI assets into revenue-generating products to validate its business model.

02
Expand consulting and cloud service capabilitiesshort-term

Services can provide near-term customer relationships and potentially fund product development.

03
Use acquisitions and licensing to accelerate developmentmedium-term

The company is building capability through external assets rather than only organic R&D.

04
Establish a scalable operating modelmedium-term

A scalable platform is necessary to support growth without proportionate cost increases.

AVAI BIO faces the classic risks of an early-stage technology company: limited operating history, uncertain...

high

Limited operating history and start-up execution risk

The company has little revenue history and is still building its business model, making forecasting and scaling difficult.

Scope
All operations
Materiality
high
high

Inability to commercialize acquired technologies

Management states that Avant! AI and other acquired assets may not generate revenue despite investment.

Scope
AI platforms and digital assets
Materiality
high
high

Dependence on external financing

The company relies on equity and convertible debt to fund operations, which can be dilutive and restrictive.

Scope
Corporate funding
Materiality
high
medium

Internal control and reporting weaknesses

Disclosure controls were reported as not effective due to limited resources and reliance on consultants.

Scope
Financial reporting
Materiality
medium
medium

Acquisition and integration risk

The strategy depends on acquiring and assimilating technology assets, which can fail or create delays.

Scope
M&A and product development
Materiality
medium
Revenue recognition under ASC 606
Could affect when revenue is reported and how quarterly results fluctuate
Valuation and impairment of acquired intangibles
Could materially change asset values and earnings
Convertible debt and preferred stock accounting
Could affect dilution, liabilities, and non-cash charges
Use of estimates and judgments
Could cause volatility in reported expenses and asset values

ANVI GLOBAL HOLDINGS, INC.

ANVI · Retail-Food Stores

AI Technology Group Inc.

Motors & Generators

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

Hestia Insight Inc.

HSTA · Services-Management Consulting Services

EVENTIKO INC.

Services-Miscellaneous Amusement & Recreation

Lunai Bioworks Inc.

LNAI · Pharmaceutical Preparations

: 11/08/2026